Aligos Therapeutics (ALGS) Total Current Liabilities (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Total Current Liabilities came in at $23.3 million in Q1 2026, up 23.08% YoY from $18.9 million in Q1 2025, and up 9.84% on a QoQ basis from $21.2 million in Q4 2025.
Aligos Therapeutics (ALGS) Total Current Liabilities (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 8 years of Total Current Liabilities data on file, last reported at $23.3 million in Q1 2026.
- Quarterly Total Current Liabilities rose 23.08% year-over-year to $23.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.3 million (up 23.08% YoY) and the FY2025 annual result came in at $21.2 million, down 2.32% from the prior year.
- Total Current Liabilities rose to $23.3 million in Q1 2026, from $21.2 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $41.4 million in Q1 2022 to a low of $18.9 million in Q1 2024.
- A 5-year average of $25.2 million and a median of $23.3 million in 2026 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities soared 63.91% — and 2024, when it tumbled 32.76%.
- Tracing ALGS's Total Current Liabilities over 5 years: stood at $33.1 million in 2022, then fell by 27.84% to $23.9 million in 2023, then retreated by 9.07% to $21.7 million in 2024, then declined by 2.32% to $21.2 million in 2025, then increased by 9.84% to $23.3 million in 2026.
- The last three Total Current Liabilities figures came in at $23.3 million (Q1 2026), $21.2 million (Q4 2025), and $22.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.56 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.72 Bn | 60.53 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.75 Bn | 53.61 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.59 Bn | 10.19 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.63 Bn | 26.47 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.40 Bn | - | 630.93 Mn |
| 10 | Aligos Therapeutics | 66.76 Mn | 36.32 Mn | - | 28.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.34 Mn |
| Mar 31, 2026 | 23.32 Mn |
| Dec 31, 2025 | 21.23 Mn |
| Sep 30, 2025 | 21.99 Mn |
| Jun 30, 2025 | 20.27 Mn |
| Mar 31, 2025 | 18.95 Mn |
| Dec 31, 2024 | 21.74 Mn |
| Sep 30, 2024 | 20.96 Mn |
| Jun 30, 2024 | 23.56 Mn |
| Mar 31, 2024 | 18.88 Mn |
| Dec 31, 2023 | 23.91 Mn |
| Sep 30, 2023 | 22.47 Mn |
| Jun 30, 2023 | 27.23 Mn |
| Mar 31, 2023 | 28.08 Mn |
| Dec 31, 2022 | 33.13 Mn |
| Sep 30, 2022 | 30.54 Mn |
| Jun 30, 2022 | 31.65 Mn |
| Mar 31, 2022 | 41.36 Mn |
| Dec 31, 2021 | 38.96 Mn |
| Sep 30, 2021 | 34.78 Mn |